dpp 4 inhibitors and glp 1 vs GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? The Role of GLP-1, DPP-4, – Mechanism of action for GIP,

IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

The average is about 1-2 pounds per week, and the typical person will lose about 15% of their body weight by 3-6 months and potentially 20% or more in a year

Tirzepatide demonstrated remarkable weight-reducing efficacy in randomized controlled trials such as SURMOUNT-1 and SURMOUNT-2, with mean body-weight reductions ranging from 15 to 22.5% ( 4.3 Modulation of inflammatory status by tirzepatide Beyond metabolic regulation, obesity-related OSAS is closely linked to chronic low-grade systemic inflammation driven by intermittent hypoxia

Lustig alerted our listeners to the muscle loss problem and other side effects of GLP-1 weight loss drugs